title: Mammalian target of rapamycin (mTOR) inhibition does not prevent lung adenocarcinoma-induced malignant pleural effusion.
abstract: The impact of temsirolimus was investigated in a murine model of malignant pleural effusion (MPE) created with intrapleural injection of Lewis Lung Cancer (LLC) cells. Temsirolimus (1 or 20 mg/kg) did not affect the pleural fluid volume or the number of pleural tumour foci. In addition, temsirolimus did not affect vascular endothelial growth factor expression by LLC cells in vitro. In conclusion, temsirolimus did not curtail experimental lung-adenocarcinoma-induced MPE.
authors.affiliation: 1st Department of Critical Care and Pulmonary Services, School of Medicine, Evangelismos Hospital, University of Athens, Athens, Greece.
authors.forename: Maria-Eleni
authors.initials: ME
authors.lastname: Vazakidou
authors.affiliation: 1st Department of Critical Care and Pulmonary Services, School of Medicine, Evangelismos Hospital, University of Athens, Athens, Greece.
authors.forename: Sofia
authors.initials: S
authors.lastname: Magkouta
authors.affiliation: 1st Department of Critical Care and Pulmonary Services, School of Medicine, Evangelismos Hospital, University of Athens, Athens, Greece.
authors.forename: Charalambos
authors.initials: C
authors.lastname: Moschos
authors.affiliation: 1st Department of Critical Care and Pulmonary Services, School of Medicine, Evangelismos Hospital, University of Athens, Athens, Greece.
authors.forename: Ioannis
authors.initials: I
authors.lastname: Kalomenidis
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D000077192:Adenocarcinoma of Lung; D000818:Animals; D045744:Cell Line, Tumor; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009374:Neoplasms, Experimental; D016066:Pleural Effusion, Malignant / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D020123:Sirolimus / Q000627:therapeutic use*; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D007166:Immunosuppressive Agents; C546843:mTOR protein, mouse; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus
keywords: animal model; lung cancer; molecular biology; pleural disease